Trial Profile
Pharmacokinetics, safety and tolerability of human recombinant alkaline phosphatase in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2016
Price :
$35
*
At a glance
- Drugs Ilofotase alfa (Primary)
- Indications Acute kidney injury
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms recAP
- 17 May 2016 New trial record
- 10 May 2016 Safety and pharmacokinetic data published in an AM-Pharma media release.
- 04 May 2016 Results published in the Clinical Pharmacokinetics